Clinical research
Mirati Therapeutics tapped David Meek, the former chief executive officer of Ipsen, as its new CEO. He replaces company founder Charles Baum.
Patients with different forms of breast cancer could soon have different treatment options following multiple presentations at the European Society of Medical Oncology meeting.
The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.
Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.
In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021.
The FDA’s IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.
The company indicates that the overall data from the vixotrigine program will help them determine dose levels for future Phase III trials.
Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.
PRESS RELEASES